Sabby Management LLC lessened its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 45.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 97,704 shares of the biotechnology company’s stock after selling 81,923 shares during the quarter. Sabby Management LLC owned 1.56% of Aldeyra Therapeutics worth $454,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the period. Virtu KCG Holdings LLC acquired a new position in Aldeyra Therapeutics in the second quarter valued at about $104,000. Renaissance Technologies LLC acquired a new position in Aldeyra Therapeutics in the first quarter valued at about $132,000. Hikari Power Ltd raised its stake in Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 70,196 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its stake in Aldeyra Therapeutics by 31.0% in the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares in the last quarter. 40.32% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/17/sabby-management-llc-sells-81923-shares-of-aldeyra-therapeutics-inc-aldx.html.

In related news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the business’s stock in a transaction on Tuesday, September 19th. The stock was acquired at an average price of $7.25 per share, for a total transaction of $1,450,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 28.40% of the stock is owned by company insiders.

Aldeyra Therapeutics, Inc. (ALDX) traded down 4.86% on Tuesday, reaching $6.66. The company had a trading volume of 94,314 shares. The stock’s 50-day moving average price is $6.63 and its 200-day moving average price is $5.10. Aldeyra Therapeutics, Inc. has a 12-month low of $3.80 and a 12-month high of $11.90. The stock’s market capitalization is $41.59 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.02. On average, equities research analysts anticipate that Aldeyra Therapeutics, Inc. will post ($1.51) EPS for the current fiscal year.

A number of research firms recently commented on ALDX. Zacks Investment Research downgraded Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. HC Wainwright set a $18.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine downgraded Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Cowen and Company reaffirmed an “outperform” rating and issued a $14.00 price target (up previously from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $27.00 price target (up previously from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.95.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.